Jazz Pharmaceuticals and Hikma Pharmaceuticals are facing an antitrust lawsuit alleging they conspired to delay the release of a generic version of Jazz’s narcolepsy drug, Xyrem, resulting in higher prices for health plans. The case will proceed to trial after a judge dismissed some claims. Plaintiffs argue that Jazz violated antitrust laws by making payments to delay generic competition and monopolizing distribution.
Jazz Pharmaceuticals’ Epidiolex, a cannabidiol oral solution for treating rare forms of epilepsy, showed mixed results in a Phase 3 trial in Japan. While the trial did not achieve its primary goal of reducing seizure frequency, there were improvements in other areas, and no new safety concerns were identified. The company plans to continue collecting data and engage with Japanese regulatory authorities regarding a potential new drug application.
